Ionis Pharmaceuticals, Inc. Common Stock
IONS Real Time Price USDRecent trades of IONS by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in IONS holdings by institutional investors
Quarterly net insider trading by IONS's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$140,000 Oct 15, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$90,000 Jul 16, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$90,000 Apr 16, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$80,000 Jan 16, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$80,000 Oct 15, 2024 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
IONS Estimated quarterly lobbying spending
IONS Revenue by Segment or Geography
New IONS patent grants
-
Patent Title: Antisense modulation of ptp1b expression Jun. 23, 2020
-
Patent Title: Modulation of cd40 expression Mar. 26, 2019
-
Patent Title: Compositions and methods for modulating growth hormone receptor expression Jun. 12, 2018
-
Patent Title: Methods and compounds useful in conditions related to repeat expansion May. 22, 2018
-
Patent Title: Methods for modulating c9orf72 expression May. 08, 2018
-
Patent Title: Compositions and methods for modulating apolipoprotein (a) expression May. 01, 2018
-
Patent Title: Compositions and methods for modulating angiopoietin-like 3 expression May. 01, 2018
-
Patent Title: Targeted therapeutic nucleosides and their use Apr. 17, 2018
-
Patent Title: 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations Apr. 17, 2018
-
Patent Title: 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations Apr. 17, 2018
-
Patent Title: Compositions and methods for modulating apolipoprotein c-iii expression Apr. 03, 2018
-
Patent Title: Compositions and methods for modulating hbv expression Apr. 03, 2018
-
Patent Title: Linkage modified oligomeric compounds Mar. 27, 2018
-
Patent Title: Compositions and their uses directed to huntingtin Mar. 20, 2018
-
Patent Title: Oligomeric compounds comprising bicyclic nucleotides and uses thereof Mar. 13, 2018
-
Patent Title: Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile Mar. 06, 2018
-
Patent Title: Modulation of tmprss6 expression Feb. 06, 2018
-
Patent Title: Methods and compositions for modulating apolipoprotein (a) expression Feb. 06, 2018
-
Patent Title: Methods and compositions for modulating apolipoprotein (a) expression Feb. 06, 2018
-
Patent Title: Cancer treatment Jan. 23, 2018
-
Patent Title: Compositions and methods for modulation of lmna expression Jan. 02, 2018
-
Patent Title: Compounds and methods for modulating target nuclear and sub-nuclear nucleic acid molecules in cells and animals Dec. 19, 2017
-
Patent Title: Compounds and methods for modulating target nuclear and sub-nuclear nucleic acid molecules in cells and animals Dec. 19, 2017
-
Patent Title: Antisense compounds targeting genes associated with fibronectin Nov. 28, 2017
-
Patent Title: 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations Nov. 28, 2017
-
Patent Title: Methods and compositions for modulating alpha-1 antitrypsin expression Oct. 24, 2017
-
Patent Title: Phosphorous-linked oligomeric compounds and their use in gene modulation Sep. 26, 2017
-
Patent Title: Modulation of dystrophia myotonica-protein kinase (dmpk) expression Sep. 19, 2017
-
Patent Title: Method for solution phase detritylation of oligomeric compounds Sep. 12, 2017
-
Patent Title: Gapped oligomeric compounds comprising 5′-modified deoxyribonucleosides in the gap and uses thereof Sep. 05, 2017
-
Patent Title: Oligomeric compounds and methods Aug. 22, 2017
-
Patent Title: Modulation of tmprss6 expression Aug. 08, 2017
-
Patent Title: 5′-end derivatives Aug. 08, 2017
-
Patent Title: Compositions and methods Jul. 25, 2017
-
Patent Title: Compositions comprising alternating 2′-modified nucleosides for use in gene modulation Jul. 18, 2017
-
Patent Title: Method of preparing oligomeric compounds using modified coupling protocols Jul. 11, 2017
-
Patent Title: Competitive modulation of micrornas Jul. 04, 2017
-
Patent Title: Oligomeric compounds comprising bicyclic nucleosides and uses thereof Jul. 04, 2017
-
Patent Title: Bicyclic morpholino compounds and oligomeric compounds prepared therefrom Jun. 27, 2017
-
Patent Title: Modulation of huntingtin expression Jun. 20, 2017
-
Patent Title: Compositions for modulating tau expression Jun. 20, 2017
-
Patent Title: Modulation of hepatitis b virus (hbv) expression Jun. 13, 2017
-
Patent Title: Modulation of prekallikrein (pkk) expression Jun. 06, 2017
-
Patent Title: Modulation of alpha synuclein expression May. 30, 2017
-
Patent Title: Methods for treating hypercholesterolemia May. 16, 2017
-
Patent Title: Compositions and methods for modulating tau expression May. 09, 2017
-
Patent Title: Modulation of apolipoprotein c-iii expression Apr. 18, 2017
-
Patent Title: Compounds and methods for modulating gene expression Apr. 11, 2017
-
Patent Title: Modulation of ube3a-ats expression Apr. 11, 2017
-
Patent Title: Compositions for modulating c9orf72 expression Mar. 28, 2017
Federal grants, loans, and purchases
Estimated quarterly amount awarded to IONS from public contracts
Recent insights relating to IONS
Recent picks made for IONS stock on CNBC
ETFs with the largest estimated holdings in IONS
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $IONS stock a Buy, Sell, or Hold?
- What is the price target for $IONS stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $IONS stock?
- Who owns the most shares of $IONS stock?
- What funds own $IONS stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view IONS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
- Address Carlsbad, CA
- Market Cap 12.3 billion
- Employees 927
- Industrial Classification Pharmaceutical Preparations